evipedia.ai
← Back

Topical Naringin vs. Topical Naringenin for Skin Rejuvenation

Evidence Review created on 09/07/2026 using AI4L / Opus 5

Also known as: Naringin, Naringenin, naringenin 7-O-neohesperidoside, 4’,5,7-trihydroxyflavanone, Citrus Flavanones

Motivation

Naringin and naringenin are two closely related compounds from citrus fruit — grapefruit, orange and pomelo. Naringin is the sugar-bound form; naringenin is the same core molecule with the sugar removed. Both are sold as ingredients in creams, serums and gels aimed at firmer, brighter, less weathered-looking skin. The difference matters because the attached sugar makes naringin larger and more water-loving, which raises the question of how much of it can cross the skin’s outer layer at all.

Citrus peel has been applied to skin for centuries, and modern interest grew when laboratory work showed that both compounds calm inflammation and neutralize the damaging molecules that sunlight generates in skin. Formulators then had to choose between them, and the two are often treated as interchangeable on ingredient lists.

This review examines what is known about applying each compound to human skin: how far each one penetrates, which effects have been measured in people rather than in cells or animals, what the safety record contains, where the two compounds diverge, and how much of the published work comes from parties selling them.

Benefits - Risks - Protocol - Conclusion

A short list of high-level sources that treat naringin, naringenin, or their application to skin in substantial depth.

Of the priority platforms, only Lifespan.io has published an article on either compound. FoundMyFitness carries a single study card on oral naringenin and muscle mass, Life Extension names naringenin only in passing inside articles on other subjects, and Peter Attia, Huberman Lab and Chris Kresser have nothing; none of this coverage concerns skin application.

Grokipedia

  • Naringin

    Covers naringin’s identity as a flavanone-7-O-glycoside, its role as the bitter principle of grapefruit, and its conversion to naringenin — the chemistry that underlies the penetration difference examined here.

  • Naringenin

    Gives naringenin’s molecular weight of 272.25 g/mol and its status as the sugar-free core of naringin, the two facts that most directly govern how each behaves on skin.

Examine

  • Naringenin

    Examine’s dedicated naringenin page, written by Kamal Patel, places the flavanone in its evidence context and notes that the record is mostly animal and in-vitro work rather than human trials.

No dedicated Examine article exists for naringin; Examine indexes the term only as a cross-reference to the naringenin page, and neither entry covers either compound applied to skin.

ConsumerLab

No ConsumerLab article exists for naringin or naringenin. ConsumerLab tests finished supplement and food products rather than individual cosmetic actives, and neither compound appears anywhere in its review, answer or recall archives.

Systematic Reviews

The systematic-review literature reaches this topic only indirectly, through reviews of natural actives in skin and of the two compounds’ systemic effects.

The trade-off in this topic is between a claimed rejuvenation effect and the risks of irritation, sensitization and forgone use of better-evidenced actives. Only the claimed-effect side is represented above; no systematic review or meta-analysis addresses the risk side for either compound applied to skin.

Mechanism of Action

Both are flavanones, a citrus subclass of plant polyphenols. Naringin is naringenin carrying a two-sugar tail; rhamnosidase (an enzyme that clips that sugar off), made by skin and gut bacteria, converts one to the other, but little of this happens inside the stratum corneum, the dead-cell layer forming the skin’s outer barrier.

Size and fat solubility drive the difference. Naringenin (272 daltons and fat-soluble) fits the window favoring passive diffusion through the lipid channels between barrier cells; naringin (581 daltons and water-soluble) does not. Work on quercetin glycosides shows the same pattern: the two-sugar form permeates skin far less than single-sugar forms (Yang et al., 2025).

Downstream both pull the same three levers: they quench reactive oxygen species (unstable, damaging forms of oxygen); they suppress NF-κB (nuclear factor kappa B, the master switch for inflammatory genes); and they lower AP-1 (activator protein 1, a gene switch driven by ultraviolet light) plus the matrix metalloproteinases it induces — the enzymes cutting collagen and elastin. Naringenin additionally competes with ATP (the cell’s energy currency) at ERK2 (extracellular signal-regulated kinase 2, a growth-signaling enzyme) (Jung et al., 2016).

A competing account holds that almost none of either reaches living skin from a conventional cream, so measured effects are surface antioxidant and ultraviolet-absorbing actions, not cell signaling.

Systemically both clear within two to three hours, act non-selectively across many targets, stay near the application site, and are inactivated by UGT1A1 and UGT1A9 (enzymes attaching sugar acid to speed excretion) and SULT1A1 (which attaches sulfate).

Historical Context & Evolution

Naringin entered science as a nuisance: it is the compound that makes grapefruit bitter, and citrus processors studied it mainly in order to remove it from juice, using the enzyme naringinase, which strips its sugar and yields naringenin. Neither compound was developed for skin; both were byproducts of food chemistry.

Attention shifted in the late 1980s, when grapefruit juice was found to raise blood levels of several medicines. Naringin was the first suspect, and early work reported that it inhibited the intestinal enzyme responsible. Later studies giving naringin alone did not reproduce the full effect at dietary doses, while furanocoumarins (a separate group of citrus compounds) from the same fruit produced stronger inhibition; the field now weighs both contributions, with naringin’s share generally judged minor but not absent.

That pharmacological spotlight prompted broader screening of citrus flavanones. Cell work in the 2000s showed naringenin protected cultured human skin cells from ultraviolet damage and sped clearance of ultraviolet DNA lesions (El-Mahdy et al., 2008); Brazilian and Korean groups then built stable topical naringenin formulations and demonstrated reduced ultraviolet injury in mice (Martinez et al., 2016). Naringin reached skin science by a different route — through bone, wound and skin-flap survival research — and entered cosmetics largely as a cheaper, more water-soluble citrus antioxidant. The two therefore arrived on ingredient lists by separate paths, and the assumption that they are interchangeable has never been tested head-to-head in people.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no replicated controlled human trial has measured a validated skin endpoint — wrinkle grading, corneometry, or expert-scored photodamage scales — for either compound applied to human skin.

Medium 🟩 🟩

Reduced Chemically Provoked Skin Inflammation with Naringenin

A 0.1% naringenin gel reduced the erythema (redness) and blood-flow surge triggered by a standard chemical challenge in human volunteers, measured with laser Doppler flowmetry, and outperformed chlorogenic acid, apigenin and kaempferol tested in parallel (Ruscinc et al., 2024). The proposed mechanism is quenching of reactive oxygen species plus suppression of inflammatory signaling. The evidence basis is a single small human study run alongside laboratory assays. Naringin was not tested, so the comparison rests on naringenin alone.

Magnitude: At 0.1% w/w (percent by weight) in an aqueous gel, naringenin cut the area under the blood-flow curve of the provoked response to 0.559 ± 0.290 of the untreated site (P = 0.0085, where P is the probability a result this large would arise by chance alone) and the slope of the blood-flow rise to 0.222 ± 0.178 (P = 0.0031), the only one of four polyphenols to beat the blank gel on both.

Low 🟩

Reduced Facial Sallowness and Pigment Markers with Naringin ⚠️ Conflicted

PROYA Cosmetics ran an uncontrolled 56-day trial of its four-ingredient naringin serum, reporting better lightness, sallowness and skin autofluorescence (a sugar-damage marker) in 34 participants (Ye et al., 2025). Yet naringenin-rich citrus preparations raise melanin in cells (Chiang et al., 2011). Net: brightening belongs to the formula, not naringin.

Magnitude: Over 56 days the serum raised skin lightness by 0.98% (P = 0.003), cut yellowness by 5.92% (P < 0.001) and lowered skin autofluorescence by 14.23 units (P < 0.001); naringin’s own share of these figures is unknown because no naringin-only arm was run.

Speculative 🟨

Suppression of Collagen-Degrading Enzymes with Naringenin

Naringenin blocked ultraviolet-driven collagen-cutting enzyme (matrix metalloproteinase-1) induction in cultured skin cells and reconstructed human skin, and cut wrinkling and water loss in irradiated hairless mice (Jung et al., 2016). No human data.

Faster Clearance of Ultraviolet DNA Damage

Naringenin sped removal of ultraviolet-induced DNA lesions in cultured human skin cells (El-Mahdy et al., 2008); naringin raised repair-gene expression and cut the same lesions in mouse fibroblasts (Das et al., 2020). Cell-only evidence.

Dampened Senescence Signaling in Dermal Fibroblasts

Naringenin suppressed inflammatory gene activation in human dermal fibroblasts driven into a senescent state (permanently arrested and inflammatory) (Choy et al., 2024). Skin-senescence reviews list it among candidate agents (Bulbiankova et al., 2023).

Preserved Barrier and Mitochondrial Function under Ultraviolet Stress

Topical naringenin prevented mitochondrial fragmentation, neutrophil influx and epidermal thickening in ultraviolet-exposed mice and human dermal fibroblasts (Sajeeda et al., 2024). Earlier mouse work on swelling and antioxidant defenses agrees (Martinez et al., 2016).

Accelerated Wound Closure and Reduced Scarring with Naringin

Naringin gels sped wound closure in rodents (Kumari et al., 2022) and naringin fibers lowered fibrosis markers in human dermal fibroblasts (Tottoli et al., 2023). A mouse comparison favored hesperidin (Vabeiryureilai et al., 2022).

Benefit-Modifying Factors

  • Barrier integrity: A compromised barrier — from eczema, over-exfoliation or recent procedures — raises penetration of both compounds, and disproportionately for naringin, whose size otherwise excludes it. Intact, well-lipidated skin narrows the difference toward naringenin’s favor.

  • Baseline photodamage and pigment load: Higher starting redness, sallowness and melanin index leave more measurable room for change. The one human naringin study recruited participants with visible hyperpigmentation (patches of darkened skin), where any brightening registers most readily.

  • Genetic pigment and repair variation: MC1R loss-of-function variants (the gene setting fair-skin, red-hair pigmentation) reduce natural ultraviolet defense, and ERCC1 or XPC variants (genes encoding the DNA-repair machinery both compounds are reported to support) may set how much repair help is available to gain.

  • Sex-based differences: Male facial skin is thicker and more sebaceous, which favors uptake of the fat-soluble naringenin; female facial skin thins faster after menopause and loses collagen more rapidly, enlarging the potential benefit from collagen-preserving actions.

  • Age-related considerations: Stratum corneum lipid content and turnover both fall with age, slowing penetration while increasing the collagen deficit available to address. Past roughly 65, thinner skin admits more compound but repairs damage more slowly.

  • Baseline biomarker levels: Low starting transepidermal water loss (the rate at which water escapes through skin) and high hydration readings signal a barrier that resists penetration; markedly elevated skin autofluorescence signals a high sugar-damage load.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome for either compound has been documented in more than one controlled human trial of topical use — the human safety record consists only of tolerability observations embedded in single small studies.

Medium 🟥 🟥

No risk reaches Medium either: no single controlled human trial and no consistent observational dataset reports a specific adverse event attributable to topical naringin or topical naringenin.

Low 🟥

Allergic Contact Dermatitis and Local Irritation

Botanically derived cosmetic actives are a recognized and rising cause of allergic contact dermatitis (a delayed, immune-driven rash), with oxidized polyphenols among the documented sensitizers (Ezzat et al., 2026). Neither flavanone is a named allergen; a 0.1% naringenin gel rated non-irritating in an in-vitro assay (Ruscinc et al., 2024).

Magnitude: Not quantified in available studies. No patch-test series or post-marketing surveillance has estimated a sensitization rate for either compound, because neither is included in the standard cosmetic patch-test panels from which such rates are derived.

Speculative 🟨

Barrier Disruption from Penetration-Enhancing Vehicles

Delivering either compound in useful amounts requires ethanol-rich ethosomes, surfactant microemulsions or elastic liposomes (Gollavilli et al., 2020). Such carriers can strip skin lipids, though only animal irritation testing has been reported.

Cytotoxicity at High Applied Concentrations

High naringenin concentrations killed normal skin cells and drove apoptosis (programmed cell death) in culture, while low concentrations did not (Sun et al., 2023). No safe upper concentration has been established for human skin.

Photosensitizing Contaminants in Citrus-Derived Raw Material

Citrus peel extracts can carry furanocoumarins, which cause phototoxic burns (chemical sunburn) on sun-exposed skin. Purified naringin and naringenin should be free of them, but no batch-level survey of cosmetic-grade material has been published.

Hormonal Signaling from Systemic Absorption

Naringenin weakly binds estrogen receptors and inhibits aromatase (the estrogen-making enzyme) in cell assays. Whether facial application delivers enough to matter systemically has never been measured.

Risk-Modifying Factors

  • Genetic polymorphisms: FLG variants (the gene for filaggrin, the skin’s main barrier protein) produce a leaky barrier admitting more applied compound. NAT2 slow-acetylator status (slower chemical detoxification) is linked to higher contact allergy rates.

  • Baseline biomarker levels: Elevated transepidermal water loss above roughly 15 g/m²/h on facial skin marks a barrier that will admit more compound and more vehicle, raising both irritation and sensitization risk.

  • Sex-based differences: Women are diagnosed with cosmetic contact dermatitis considerably more often than men, driven largely by higher product counts and more frequent application rather than by intrinsic skin differences.

  • Pre-existing health conditions: Atopic dermatitis, rosacea, seborrheic dermatitis and active photodermatoses (rashes provoked by light) all lower the irritation threshold. A prior reaction to propolis or citrus peel signals cross-reactivity risk.

  • Age-related considerations: Older skin mounts weaker sensitization responses but recovers from irritation far more slowly, so a reaction past 65 persists longer even though it is less likely to begin.

Key Interactions & Contraindications

  • Topical retinoids (tretinoin, adapalene, tazarotene): Caution; additive barrier disruption produces stinging, scaling and erythema. Mitigation: alternating nights rather than layering, with the flavanone in the morning if the retinoid is nightly.

  • Topical hydroxy acids (glycolic acid, lactic acid, salicylic acid): Caution; a lowered stratum corneum pH and thinned barrier raise flavanone penetration unpredictably and compound irritation. Mitigation: separation by at least twelve hours, or use on alternate days.

  • Over-the-counter retinol and benzoyl peroxide: Caution; benzoyl peroxide is a strong oxidizer that degrades polyphenols on contact, wasting the active and generating irritant byproducts. Mitigation: separate routines, morning versus evening.

  • Topical antioxidant supplements (L-Ascorbic acid, ferulic acid, resveratrol, green tea catechins): Caution; additive antioxidant effect, but the low pH these agents require and their oxidation products raise stinging and irritation risk. Mitigation: single antioxidant serum per routine, airless packaging.

  • Oral citrus flavanone supplements and grapefruit juice: Monitor; concurrent oral intake, not topical use, is what engages CYP3A4 (a liver and gut enzyme that breaks down many medicines) and can raise levels of statins, calcium-channel blockers and some immunosuppressants.

  • Energy-based and mechanical procedures (fractional laser, microneedling, chemical peels): Absolute contraindication on freshly wounded skin; a breached barrier admits both active and vehicle directly to living tissue, sharply raising sensitization risk. Mitigation: withholding for 14 days after ablative procedures.

  • Other topical actives with pigment effects (hydroquinone, azelaic acid, tranexamic acid): Monitor; the direction of naringenin’s pigment effect is unresolved, so pairing it with a depigmenting agent may blunt or confuse the result. Mitigation: changing one variable at a time.

Populations who should avoid Topical Naringin vs. Topical Naringenin:

  • Anyone with a positive patch test to citrus peel, propolis or a related flavonoid
  • Active eczema flare on the intended application site (roughly SCORAD above 25, a validated eczema severity score)
  • Within 14 days of ablative laser resurfacing, medium-depth peel or full-face microneedling
  • Broken, weeping or infected skin at the application site
  • Infants and children under 12, for whom no topical safety data of any kind exist

Risk Mitigation Strategies

  • Repeat open application test before facial use: Protocols apply the product twice daily to a 2 cm² inner-forearm patch for five days, inspected at 48 and 96 hours, screening for the delayed allergic contact dermatitis identified as the principal risk.

  • Low end of the cosmetic range first: Protocols start at 0.05–0.1% w/w naringenin or 0.1–0.5% w/w naringin and hold for four weeks before increasing, limiting both irritation and the cytotoxicity seen at high concentrations in culture.

  • Capped application frequency during introduction: Once-daily use for the first two weeks, then twice daily, lets barrier disruption from penetration-enhancing vehicles become apparent before cumulative exposure builds.

  • Simple vehicles first: An aqueous or light emulsion base is the conservative starting point over ethanol-rich ethosomes and high-surfactant microemulsions, which raise delivery but carry the lipid-stripping risk described in the Risks section.

  • Furanocoumarin testing on citrus-derived raw material: A certificate of analysis showing bergapten below 1 part per million addresses the phototoxic-burn risk from residual peel constituents.

  • Protection of the formulation from oxidation: Opaque, airless packaging and disposal three months after opening address oxidized polyphenols, which are the documented sensitizing form rather than the parent compound.

  • Withholding around procedures and flares: Suspension 7 days before and 14 days after any ablative or needling procedure, and during any eczema or rosacea flare, prevents direct delivery to breached skin.

Therapeutic Protocol

  • Standard formulation approach: Cosmetic chemists working with these actives use naringenin at 0.05–0.5% w/w in a light emulsion or aqueous gel, and naringin at 0.1–1.0% w/w, the higher figure reflecting its poorer delivery rather than greater potency.

  • Competing approach — sugar-free form first: One camp uses naringenin directly, accepting solubility problems in exchange for a molecule already sized for passive entry, as in the 0.1% gel tested on human volunteers.

  • Competing approach — glycoside plus carrier: The other uses naringin inside ethosomes, proposomes or elastic vesicles, accepting formulation complexity in exchange for stability, water solubility and lower raw-material cost.

  • Groups that popularized each route: The Casagrande and Verri group at Universidade Estadual de Londrina established topical naringenin formulations; the Mutalik group at Manipal developed naringin ethosomal sunscreens; the Baby group in São Paulo carried naringenin into human testing.

  • Best time of day: Morning application aligns with the ultraviolet and visible-light exposure both compounds are proposed to buffer; evening application avoids competition with sunscreen layering. Neither timing has been compared head to head.

  • Expected half-life: Systemic clearance runs roughly two to three hours for both, but the relevant figure is the skin depot, which persists far longer — ethosomal naringin remained in skin at measurable levels with negligible transdermal passage.

  • Single versus split application: Split dosing, morning and evening, is standard because the skin reservoir is shallow and surface loss to washing, sweat and transfer is continuous. Once-daily use is the conventional introduction schedule.

  • Genetic polymorphisms influencing protocol: MC1R variants (fair skin, poor tanning) argue for morning use under sunscreen; FLG variants (leaky barrier) argue for lower starting concentrations and simpler vehicles regardless of which compound is chosen.

  • Sex-based differences in response: Thicker, more sebaceous male facial skin favors naringenin uptake and tolerates higher concentrations; post-menopausal female skin is thinner and more reactive, arguing for the lower end of each range.

  • Age-related considerations: Above roughly 65, thinner skin admits more compound while repairing irritation more slowly, so protocols start at half the usual concentration and extend the introduction period to six weeks.

  • Baseline biomarker levels: A starting transepidermal water loss above 15 g/m²/h indicates a barrier that will over-deliver; protocols in that situation begin with barrier repair for four weeks before introducing either flavanone.

  • Pre-existing health conditions: Rosacea and atopic dermatitis shift the choice toward the lowest concentration in the simplest vehicle, and toward naringenin, whose only human tolerability data come from an aqueous gel.

Discontinuation & Cycling

  • Intended duration: Both are used as indefinite maintenance actives rather than a course of treatment, because the proposed mechanisms — antioxidant buffering and enzyme suppression — operate only while the compound is present in skin.

  • Withdrawal effects: None documented. Neither compound engages a receptor system that adapts to chronic exposure, and no rebound erythema, pigmentation or barrier deterioration has been reported after stopping.

  • Tapering protocol: Not applicable; abrupt discontinuation is standard practice and carries no reported consequence. Where a reaction prompts stopping, the relevant step is barrier repair, not a graded reduction.

  • Cycling for maintained efficacy: No tolerance mechanism has been identified, so cycling has no efficacy rationale. Periodic pauses of two to four weeks serve a different purpose — unmasking a slowly developing contact allergy that daily use would obscure.

  • Seasonal adjustment: Some formulators concentrate use in high-ultraviolet months on the premise that the light-buffering effect is what matters, though no study has compared seasonal with year-round use.

Sourcing and Quality

  • Purity specification: Cosmetic-grade material should be specified at 95% or higher by high-performance liquid chromatography, a separation technique that quantifies each component. Food-grade naringin is frequently sold at 80–90% with unspecified citrus co-extractives.

  • Origin and production route: Naringin is extracted from the peel of Citrus paradisi and Citrus maxima; naringenin is produced either by enzymatic hydrolysis of naringin using naringinase or by microbial fermentation. Fermentation-derived material avoids peel contaminants entirely.

  • Furanocoumarin testing: Peel-derived material must carry a certificate of analysis for bergapten and related furanocoumarins, since these travel with citrus extracts and are the source of the phototoxicity risk rather than the flavanones themselves.

  • Safety-panel review status: Neither compound has a published Cosmetic Ingredient Review assessment. That panel, the main United States body reviewing cosmetic ingredient safety, is funded by the Personal Care Products Council, the trade association whose members sell the ingredients it reviews.

  • Third-party verification: Neither compound is covered by ConsumerLab, United States Pharmacopeia or NSF International certification programs, so verification depends on the supplier’s certificate of analysis and, where available, independent laboratory confirmation of identity and assay.

  • Reputable supply channels: Sigma-Aldrich and TCI supply analytically characterized reference-grade material; cosmetic ingredient houses such as Symrise and BASF supply formulation-grade citrus flavanones. Compounding pharmacies will prepare custom concentrations from characterized raw material.

  • Formulation stability: Only one of three naringenin formulations tested held its physical and antioxidant properties over 180 days (Martinez et al., 2016), so opaque airless packaging and a stated stability period are quality signals rather than marketing detail.

  • Avoiding undefined blends: Products labeled only “citrus bioflavonoids” or “grapefruit extract” do not disclose the naringin-to-naringenin ratio, which is the single variable this review turns on. A named compound with a stated percentage is the minimum useful label.

Practical Considerations

  • Time to effect: The one human anti-inflammatory signal appeared after a single application; the one human pigment and sugar-damage study ran 56 days. Any collagen-related change, if real, would follow the 12-week minimum that applies to all topical actives.

  • Common pitfall — assuming equivalence: Ingredient lists treat the two as interchangeable, but the sugar on naringin roughly doubles its molecular weight and removes its fat solubility. A naringin product without a delivery system is a different proposition from a naringenin one.

  • Common pitfall — layering onto an irritated barrier: Adding a flavanone serum to a routine already containing a retinoid and an acid produces irritation attributed to the new ingredient, when the cause is cumulative barrier load.

  • Common pitfall — yellow staining: Both compounds are pale yellow and transfer to pillowcases and light fabrics at higher concentrations. This is cosmetic rather than harmful, but it drives discontinuation more often than any adverse effect.

  • Regulatory status: Both are cosmetic ingredients in the United States and are listed in the European cosmetic ingredient database. Neither is an approved drug for any skin indication, so no efficacy claim has passed a regulatory review anywhere.

  • Cost and accessibility: Neither is expensive or hard to obtain; naringin costs a fraction of naringenin as raw material, and finished products sit within ordinary serum pricing. Neither is reimbursed by any insurer or national health system.

  • Absence of payer influence: Because no institutional payer covers either compound, no insurer or health system has a financial incentive to favor one over the other, and neither appears in reimbursement-driven guidelines; structural payer bias is absent here.

Interaction with Foundational Habits

  • Sleep: No direct interaction; neither compound is absorbed in amounts that reach the brain from facial application. Indirectly, overnight is when barrier repair and collagen synthesis peak, so evening application coincides with the period when a delivered active would meet the most active cells.

  • Nutrition: Direct overlap in exposure. Oral citrus intake — grapefruit, oranges, pomelo — supplies the same two compounds systemically, and dietary naringin is converted to naringenin by gut bacteria. This raises systemic background but adds nothing to skin concentrations, which depend entirely on what is applied.

  • Exercise: Indirect and blunting. Sweat and post-exercise cleansing strip the shallow skin reservoir both compounds form, and occlusive sportswear plus friction raise irritation risk from penetration-enhancing vehicles. Practical approach: apply after showering rather than before training, and avoid application under headbands or helmet padding.

  • Stress management: Indirect and potentiating. Psychological stress raises cortisol, which impairs barrier recovery and amplifies the inflammatory signaling both compounds are proposed to suppress. Skin under sustained stress is therefore both more reactive to the vehicle and, in principle, has more inflammation available to reduce.

Monitoring Protocol & Defining Success

Because these are cosmetic actives applied to a visible organ, monitoring is instrument-based and skin-local rather than laboratory-based; no blood test tracks topical flavanone use. A baseline set is established before the first application: a standardized photograph under fixed lighting, a barrier and hydration reading, objective redness and pigment readings, and, where a device is available, a sugar-damage reading. A repeat open application test on the inner forearm over five days precedes facial use, screening for delayed allergy. Ongoing measurement follows at 4 weeks, 8 weeks and 12 weeks, then every 3–6 months, always at the same site, at the same time of day, and after 20 minutes of acclimatization in a room held at stable temperature and humidity. Any new redness, itch or scaling triggers immediate reassessment rather than waiting for the next scheduled timepoint.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Transepidermal water loss Under 15 g/m²/h on cheek skin Barrier integrity; governs how much compound and vehicle enters Transepidermal water loss is the rate at which water escapes through skin. Requires 20 minutes acclimatization at 20–22 °C and 40–50% relative humidity. Conventional dermatology sets no reference range at all
Stratum corneum hydration (corneometry) Above 45 arbitrary units on cheek skin Detects vehicle-driven drying before visible flaking appears Corneometry measures the electrical capacitance of the outer skin layer. Paired with transepidermal water loss; measured before cleansing, not after
Erythema index (a* value) No established target; track change from the individual’s own baseline, with success defined as a lower value than baseline Objective measure of the inflammation both compounds are proposed to reduce Erythema index is an instrument-derived redness score. Same device, same three sites, same lighting. Best paired with the hydration reading in one sitting
Melanin index or individual typology angle No established target; track change from the individual’s own baseline in either direction The pigment effect is conflicted, so direction matters as much as size Individual typology angle is a calculated skin-tone value. Taken before any sun exposure that day; seasonal tanning confounds readings taken months apart
Skin autofluorescence Below the age-predicted mean (roughly 0.023 × age in years + 0.8 arbitrary units) The only endpoint on which naringin has any human data Skin autofluorescence estimates accumulated advanced glycation end-products, sugar-damaged proteins in the dermis. Measured on the inner forearm; no fasting required
Repeat open application test result No reaction at 48 and 96 hours Detects the delayed allergic contact dermatitis that is the principal identified risk Applied twice daily for five days to a 2 cm² inner-forearm patch. Repeated annually, since sensitization can develop after months of uneventful use

Qualitative markers tracked alongside the instrument readings:

  • Stinging or burning within minutes of application, and whether it resolves or accumulates across weeks
  • Subjective smoothness and “grip” of the skin surface on waking, before any product is applied
  • Makeup behavior — whether foundation sits evenly or catches on flaking
  • Visible flushing triggers and whether their threshold shifts
  • Sensitivity to sun exposure at the treated site relative to untreated skin
  • Persistence of yellow transfer onto fabric, which signals over-application

Emerging Research

  • No registered trial of topical use exists: A search of ClinicalTrials.gov for naringin and naringenin returns 20 studies, all of oral intake for metabolic, vascular, cognitive or bone endpoints. Not one addresses skin application, which is the largest single gap in this evidence base.

  • Naringenin supplementation in bone fracture patients: NCT06612762 is recruiting 70 participants, with circulating inflammatory markers as the primary outcome. It will produce the first sizeable human dataset on naringenin’s anti-inflammatory effect at a whole-body level.

  • Completed human safety and pharmacokinetic work: NCT03582553 enrolled 18 participants in a randomized, double-blind, early-phase single-ascending-dose study of 150–900 mg of a citrus naringenin extract, establishing tolerability and blood levels that bound any systemic exposure from topical use.

  • Energy expenditure and safety follow-on: NCT04697355 examined naringenin with beta carotene for energy expenditure and treatment-emergent adverse events, but enrolled a single participant and posted no results, so it adds almost nothing to the safety picture.

  • Delivery chemistry that could strengthen the case: Combining naringenin with hesperetin as a coamorphous pair inside a microemulsion raised skin permeation of both by more than fourfold (Uchiyama et al., 2023). If replicated on human skin, this would remove the delivery objection that currently limits both compounds.

  • Findings that could weaken the case: Naringenin-enriched citrus preparations stimulated melanin production and expression of tyrosinase (the enzyme that makes melanin) in pigment cells (Chiang et al., 2011), and high naringenin concentrations killed normal skin cells in culture (Sun et al., 2023). Both need resolution in human skin.

  • Visible-light protection as the next test: A recent systematic review found the strongest clinical photoprotection evidence across natural compounds sits with polyphenols and calls for standardized phototesting (Rodríguez-Luna et al., 2026). Such protocols would give these two compounds their first comparable human endpoint.

Conclusion

Naringin and naringenin are the same citrus molecule with and without an attached sugar, and that single difference dominates everything else. The sugar-free form is small enough and fat-soluble enough to cross the skin’s outer layer on its own; the sugar-bound form is roughly twice the size, dissolves in water rather than fat, and needs an engineered carrier to get anywhere at all.

The laboratory case is interesting for both: they calm inflammatory signaling, quench damaging oxygen species, suppress the enzymes that cut collagen, and speed repair of sun-induced damage to the genetic material in skin cells. Almost all of it sits in cell cultures and mice.

In people, the evidence thins dramatically. One small study found a sugar-free naringenin gel reduced a provoked redness response better than three rival plant antioxidants. One uncontrolled study found a four-ingredient serum containing the sugar-bound form brightened skin over eight weeks, and the company selling that serum ran it. The pigment findings point in opposite directions depending on which form was tested. The safety record is thin rather than reassuring: a delayed allergic rash, irritation from the carriers the sugar-bound form needs, and sun-sensitizing residues citrus peel can carry. Beyond that one commercial study the published work is academic, though the main panel reviewing cosmetic ingredient safety is funded by the industry trade body whose members make them. No trial has ever compared the two forms directly on human skin, and no insurer or health system has a stake in the answer.

Top - Benefits - Risks - Protocol